The Latest Breaking News from BMY

With Buffett having officially stepped down at Berkshire Hathaway, investors might continue to follow his lead when it comes to these popular names.

Bristol-Myers Squibb is poised to announce its fourth-quarter results next month, and analysts predict a single-digit decline in the company’s bottom-line figure.

Bayer AG (OTC:BAYRY) released topline results from the Phase 3 OCEANIC-STROKE study, with its investigational, once daily, oral FXIa inhibitor asundexian.

Bristol Myers Squibb Co. (NYSE:BMY), in collaboration with Johnson Johnson (NYSE:JNJ), announced Friday that they decided to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added to the standard of care (conventional antiplatelet therapy) for patients after a recent acute coronary syndrome (ACS)…

Among Wednesday’s 35 most unusually active options, two emerged as notable straddle setups appealing to both bullish and bearish traders. These potential plays revolve around some of the market’s most familiar and widely followed stocks.

Bristol-Myers Squibb has significantly underperformed the broader market over the past year, and analysts are cautious about the stock’s prospects.

While fundamental and technical analyses dominate the finance ecosystem, there’s another, more powerful mechanism to succeed in the markets.

Bristol-Myers Squibb is set to release its third-quarter results by the end of this month, and analysts expect a notable double-digit drop in earnings.

Bristol Myers Squibb Co. (NYSE:BMY) on Friday agreed to acquire Orbital Therapeutics, a privately held biotechnology company focused on RNA medicines that reprogram the immune system in vivo.